Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
NEW YORK , Oct. 26, 2023 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CM Life Sciences III Inc. ("CM Life Sc...
Are you looking for the best penny stocks to buy now? Today might be your day...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of EQRx, Inc. (...
SAN DIEGO--(BUSINESS WIRE)---- $EQRX #CMLifeSciencesIIIInc--EQRx, Inc. (EQRX) May Have Engaged in a Conflicted SPAC Process....
EQRx (EQRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of EQRx, Inc. (...
MILWAUKEE , Aug. 2, 2023 /PRNewswire/ -- Ademi LLP is investigating EQRx (Nasdaq: EQRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Revolution Medicine...
Penny stocks are an interesting asset class. On any given day, you will see at least a handful experiencing extreme levels and explosive moves....
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of EQRx, Inc. (NASDAQ: EQRX) and Revolution Medicines, Inc. is fair to EQRx shareholders. ...
